Last reviewed · How we verify
Preserved Bimatoprost 0.01%
Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.
Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Preserved Bimatoprost 0.01% |
|---|---|
| Also known as | BIMMD, Lumigan 0.01 % |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bimatoprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral (unconventional) pathway. This increased outflow reduces intraocular pressure, making it effective for glaucoma and ocular hypertension. The preserved formulation contains antimicrobial preservatives to maintain sterility.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation increase
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Periocular skin pigmentation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preserved Bimatoprost 0.01% CI brief — competitive landscape report
- Preserved Bimatoprost 0.01% updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI